Seres Therapeutics (MCRB) Operating Margin: 2016-2025
Historic Operating Margin for Seres Therapeutics (MCRB) over the last 8 years, with Sep 2025 value amounting to -6,403.70%.
- Seres Therapeutics' Operating Margin was N/A to -6,403.70% in Q3 2025 from the same period last year, while for Sep 2025 it was -96,662.62%, marking a year-over-year change of. This contributed to the annual value of -154.44% for FY2023, which is 236961.00% up from last year.
- Seres Therapeutics' Operating Margin amounted to -6,403.70% in Q3 2025, which was down 214.92% from 5,572.49% recorded in Q1 2024.
- Over the past 5 years, Seres Therapeutics' Operating Margin peaked at 5,572.49% during Q1 2024, and registered a low of -57,850.00% during Q4 2023.
- In the last 3 years, Seres Therapeutics' Operating Margin had a median value of -9,961.24% in 2023 and averaged -14,423.90%.
- In the last 5 years, Seres Therapeutics' Operating Margin plummeted by 5,767,246bps in 2023 and then soared by 1,909,127bps in 2024.
- Seres Therapeutics' Operating Margin (Quarterly) stood at -684.56% in 2021, then skyrocketed by 50,702bps to -177.54% in 2022, then crashed by 5,767,246bps to -57,850.00% in 2023, then skyrocketed by 1,909,127bps to 5,572.49% in 2024, then reached -6,403.70% in 2025.
- Its last three reported values are -6,403.70% in Q3 2025, 5,572.49% for Q1 2024, and -57,850.00% during Q4 2023.